Although some markers of disease progression like BCR-ABL kinase domain mutations and some non-BCR-ABL gene mutations like ASXL1, GATA2, etc., have been reported, no exclusively specific and universal molecular biomarkers exist for the timely detection of CML patients at risk of disease progression [14,15]. This evidence concerns the gene GATA2 and chronic myelogenous leukemia, BCR-ABL1 positive.